Top Page
Arbutus Biopharma
(NASDAQ:ABUS)
Arbutus Biopharma (ABUS) vs. SPDR S&P 500 ETF (SPY)
Arbutus Biopharma Business Overview & Revenue Model
Arbutus Biopharma Earnings Call Summary
Arbutus Biopharma Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.42M | 6.17M | 18.14M | 39.02M | 10.99M | 6.91M |
| Gross Profit | 6.11M | 4.79M | -55.56M | 37.59M | 9.23M | -40.57M |
| EBITDA | -53.12M | -68.40M | -70.99M | -61.86M | -71.64M | -57.81M |
| Net Income | -54.25M | -69.92M | -72.85M | -69.46M | -77.35M | -65.21M |
Balance Sheet | ||||||
| Total Assets | 103.27M | 131.71M | 144.40M | 195.42M | 204.49M | 137.08M |
| Cash, Cash Equivalents and Short-Term Investments | 98.09M | 122.62M | 126.00M | 146.91M | 155.32M | 123.27M |
| Total Debt | 5.00M | 1.29M | 8.72M | 2.19M | 2.61M | 2.98M |
| Total Liabilities | 20.29M | 34.34M | 38.38M | 58.57M | 35.05M | 35.11M |
| Stockholders Equity | 82.98M | 97.37M | 106.02M | 136.85M | 169.44M | 101.97M |
Cash Flow | ||||||
| Free Cash Flow | -60.28M | -65.03M | -86.94M | -35.87M | -68.34M | -51.67M |
| Operating Cash Flow | -60.19M | -64.85M | -85.94M | -35.36M | -67.53M | -51.44M |
| Investing Cash Flow | 28.39M | 22.95M | 50.77M | -74.94M | -12.68M | -14.91M |
| Financing Cash Flow | 6.43M | 52.00M | 30.65M | 31.81M | 137.24M | 86.75M |
Arbutus Biopharma Technical Analysis
Arbutus Biopharma Risk Analysis
Arbutus Biopharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $4.15B | ― | -60.98% | ― | 338.45% | -19.64% | |
55 Neutral | $1.34B | ― | -81.20% | ― | 16.74% | 59.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $862.64M | ― | -52.82% | ― | 53.23% | 35.32% | |
48 Neutral | $1.12B | ― | -17.34% | ― | 83.36% | 22.27% | |
46 Neutral | $733.72M | ― | -31.09% | ― | 11877.28% | 63.14% | |
33 Underperform | $1.07B | ― | -109.12% | ― | ― | 7.58% |
Arbutus Biopharma Corporate Events
Arbutus Biopharma is conducting a long-term follow-up study titled ‘A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729).’ The study aims to monitor subjects with chronic hepatitis B who were previously treated with imdusiran, focusing on their health status after stopping nucleos(t)ide analogue (NA) therapy. This research is significant as it seeks to understand the long-term effects and safety of discontinuing NA therapy in these patients.
On October 7, 2025, Arbutus Biopharma announced that four abstracts featuring data on their products imdusiran and AB-101 were accepted for presentation at the American Association for the Study of Liver Diseases – The Liver Meeting 2025. The AB-101 abstract was notably selected as a Poster of Distinction. These presentations highlight the safety and potential efficacy of imdusiran in enhancing treatment responses in chronic hepatitis B patients and the promising pharmacodynamics of AB-101, which may strengthen Arbutus’s position in the biopharmaceutical industry focused on infectious diseases.
The most recent analyst rating on (ABUS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
On September 9, 2025, the U.S. District Court for the District of New Jersey issued a claim construction ruling in a lawsuit filed by Arbutus Biopharma and its licensee Genevant Sciences against Pfizer Inc. and BioNTech SE. The lawsuit alleges that Pfizer/BioNTech’s COVID-19 mRNA-based vaccines infringe on several of Arbutus’s patents related to lipid nanoparticle technology. The court’s decision on the construction of disputed patent terms could significantly impact the ongoing litigation and the companies involved, as it addresses key elements of the technology used in the COVID-19 vaccines.
The most recent analyst rating on (ABUS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly chronic hepatitis B, using its proprietary RNA interference and PD-L1 inhibitor technologies. In its latest earnings report for the quarter ending June 30, 2025, Arbutus Biopharma highlighted a significant increase in revenue, driven primarily by collaborations and licenses, with total revenue reaching $10.7 million compared to $1.7 million in the same quarter last year. Key financial metrics revealed a net income of $2.5 million, a notable improvement from a net loss of $19.8 million in the previous year, attributed to reduced operating expenses and increased collaboration revenue. The company also reported a restructuring charge related to workforce reduction and the closure of its headquarters, which contributed to a decrease in operating expenses. Looking ahead, Arbutus Biopharma remains focused on advancing its clinical programs and defending its intellectual property, with management expressing confidence in its cash resources to support operations for the next 12 months.
On August 4, 2025, Anuj Hasija resigned from Arbutus Biopharma‘s Board of Directors, with Dr. Roger Sawhney appointed as his replacement. Dr. Sawhney will also join the Audit and Corporate Governance and Nominating Committees. Arbutus reported strong financial results for the second quarter of 2025, with a significant increase in revenue due to the reacquisition of Greater China rights to imdusiran. The company is actively involved in ongoing patent infringement litigations against Moderna and Pfizer/BioNTech, seeking compensation for the use of its LNP technology.
The most recent analyst rating on (ABUS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.